To conclude, our data support the notion that PKP2 gene therapy holds promise for improving the clinical outcomes of patients with ACM with PKP2 haploinsufficiency, and reinforce the promise of gene therapy for tackling heart disease. The gene discussed is PKP2; the disease is heart disorder.